b03d2223-38c1-4bb3-be8b-27db05f87b66
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- COMPLEMENT+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- APICAL_SURFACE+0.100
- E2F_TARGETS+0.100
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- ANDROGEN_RESPONSE-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- PROTEIN_SECRETION-0.400
- TGF_BETA_SIGNALING-0.400
- UV_RESPONSE_DN-0.400
- ESTROGEN_RESPONSE_EARLY-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- HEDGEHOG_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617828 | — | D | 0.896 |
| 2 | TCGA-GM-A2DO-01A-11R-A18M-07 | — | D | 0.882 |
| 3 | SRR8613787 | — | D | 0.880 |
| 4 | s0122145 | — | — | 0.876 |
| 5 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.872 |
| 6 | e5c23a09-dd5f-4eda-8eca-f4aea9b71c20 | — | — | 0.870 |
| 7 | SRR9879287 | — | cohortA1 | 0.865 |
| 8 | SRR8518222 | — | D | 0.857 |
| 9 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.856 |
| 10 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |